Venomyx Therapeutics on Wefunder

EpiPen for snakebites: the antivenom of tomorrow!

CLOSED

see other companies in category:

visit:
Venomyx Therapeutics Website

minimum raise

$50,000

maximum raise

$1,070,000

start date

03/14/2019

stop date

07/03/2019

security type

SAFE

investment minimum

$100

raised to date

$297,421

reporting date

CLOSED

number of investors

506

percent of minimum raised

595%

percent of maximum raised

28%

likelihood of reaching max

Likely to Reach Max

dollars per day to reach max

$0

dollars per day committed

$2,679

dollars per day - category-

$2,431

dollars per day committed - all companies

$959
More SEC Filing Data on Venomyx Therapeutics from Crowdfilings.com

Venomyx Therapeutics, with a valuation cap of $5 million, is raising crowdfunding on WeFunder. The company is developing Vipax, the world’s first broad-spectrum antivenom for snakebites. The product is ten times more effective than traditional antivenoms and much cheaper. Venomyx Therapeutics was founded by Daniel Dempsey and Deepankar Roy. The proceeds of the current crowdfunding round, with a minimum raise of $50,000, will be used to complete the preclinical trials, file an application to the FDA, and finish the research. Venomyx Therapeutics is expected to be a revolution while using biotechnology, and not animals, for the production of antivenom.